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ABSTRACT
Dysglycemia results from a deficit in first-phase
insulin secretion compounded by increased
insulin insensitivity, exposing b cells to
chronic hyperglycemia and excessive glycemic
variability. Initiation of intensive insulin
therapy at diagnosis of type 2 diabetes mellitus
(T2DM) to achieve normoglycemia has been
shown to reverse glucotoxicity, resulting in
recovery of residual b-cell function. The
United Kingdom Prospective Diabetes Study
(UKPDS) 10-year post-trial follow-up reported
reductions in cardiovascular outcomes and
all-cause mortality in persons with T2DM who
initially received intensive glucose control
compared with standard therapy. In the
cardiovascular outcome trial, outcome
reduction with an initial glargine intervention
(ORIGIN), a neutral effect on cardiovascular
disease was observed in the population
comprising prediabetes and T2DM. Worsening
of glycemic control was prevented over the
6.7 year treatment period, with few serious
hypoglycemic episodes and only moderate
weight gain, with a lesser need for dual or
triple oral treatment versus standard care.
Several other studies have also highlighted the
benefits of early insulin initiation as first-line or
add-on therapy to metformin. The decision to
introduce basal insulin to metformin must,
however be individualized based on a
risk–benefit analysis. The landmark ORIGIN
trial provides many lessons relating to the
concept and application of early insulin
therapy for the prevention and safe and
effective induction and maintenance of
glycemic control in type 2 diabetes.
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INTRODUCTION
Over the last few decades, there has been a
dramatic global increase in the number of
people with pre-diabetes [characterized by
either impaired fasting glucose (IFG) or
impaired glucose tolerance (IGT)] and known
type 2 diabetes mellitus (T2DM). Dysglycemia is
associated with multiple diabetes-related
complications, cardiovascular disease (CVD),
and premature death [1, 2]. A person with
T2DM is two- to four-times more likely to
develop CVD, the major cause of death in
diabetes [1]. Morbidity associated with
microvascular complications (retinopathy,
nephropathy, and neuropathy) also represents
a major burden in T2DM [3–7]. Consequently,
dysglycemia has become a serious economic
burden and is one of today’s most important
public health challenges [1, 2].
Although intervention in IGT involving
lifestyle change [8], metformin [9], or acarbose
[10] reduces the incidence of T2DM, the effects
are not always sustained. Similar results were
seen in people with newly diagnosed type 2
diabetes in the United Kingdom Prospective
Diabetes Study (UKPDS) [3] and in A Diabetes
Outcome Progression Trial (ADOPT) [11].
Rosiglitazone, but neither glibenclamide nor
metformin, had a long-lasting effect on
preventing diabetes progression [11]. However,
together with lifestyle intervention, metformin
is still recommended as first-line therapy in
international guidelines [12] based on findings
in the UKPDS involving a relatively small
number of obese subjects who had a favorable
cardiovascular (CV) outcome on metformin [3].
In obese people with IFG, autopsy studies
reveal that more than 40% of the b-cell mass
had already been lost, while in obese and lean
people with T2DM b-cell mass was reduced by
63% and 41%, respectively [13, 14]. This is in
keeping with the 50% loss of b-cell function
when patients first present with T2DM [15]. The
deficit in b-cell function develops along a
continuum of hyperglycemia, starting below
the cutoff limits for the diagnosis of
pre-diabetes and overt diabetes [16]. Because
b-cell loss and impaired insulin secretion play a
central role in the progression of dysglycemia
from pre-diabetes to frank diabetes, a critical
appraisal of our current therapeutic
management paradigm seems appropriate at
this time. Therefore, the key intent of this
article is to address and analyze the rationale,
efficacy, safety and practicability of early insulin
therapy in people with T2DM. Central to the
discussion will be the use of basal insulin
glargine, which has recently been investigated
in the large-scale and long-term outcome
reduction with an initial glargine intervention
(ORIGIN) trial (ClinicalTrials.gov
NCT00069784) [17] and followed by a
post-trial study of the ORIGIN and Legacy
Effects (ORIGINALE) study of the earlier
interventions [18].
PATHOPHYSIOLOGY OF GLUCOSE
REGULATION: A KEY ARGUMENT
FOR EARLY INSULIN USE
In people with normal glucose tolerance, there
is a competent time-related quantitative and
qualitative b-cell response to the carbohydrate
milieu (Fig. S1). In people with dysglycemia and
diabetes, continuous glucose measurement
reveals a progressive deterioration of glucose
homeostasis that has harmful effects on both b
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cells and the endothelium (Fig. S2a) [16, 19, 20].
The underlying pathophysiology in the early
phase of glucose intolerance is a loss of pulsatile
insulin secretion and a deficit in acute insulin
response to a nutrient load (Fig. S2b) [21, 22].
During this early phase there is a dramatic
increase in insulin resistance, along with
inappropriate hyper-glucagonemia resulting in
excessive hepatic gluconeogenesis [21]. These
three factors—insulin deficit, enhanced
glucagon response, and insulin resistance—
interact in a vicious cycle, resulting in a state
of glucotoxicity and lipotoxicity
(gluco-lipo-toxicity) as driving forces for the
progressive loss of b-cell secretory capacity and
mass [23], along with the impact of
inflammation and the presence of cytokines
and amyloid [24]. With an early insulin deficit
playing such a key role, the question arises as to
whether near to normal control of fasting
plasma glucose (FPG), and/or postprandial
glucose (PPG), and/or glucose variability
can prevent or reverse this vicious cycle early
in the natural history of abnormal glucose
tolerance.
IMPACT OF HYPERGLYCEMIA
AND HYPERLIPIDEMIA: THE CASE
FOR EARLY INSULIN USE
In vitro experiments have shown that
long-lasting hyperglycemia results in
diminished insulin gene expression in b cells
[21, 25]. These glucotoxic effects are reversible
with euglycemic conditions, and the shorter the
exposure to hyperglycemia, the greater the
degree of b cell recovery [23, 26]. In addition,
hypertriglyceridemia results in significant
triglyceride stores in the islets, with a negative
impact on b-cell function [27]. Thus, both
glucotoxic and lipotoxic environments have a
deleterious effect on b-cell function.
Insulin lowers plasma free fatty acids
through its inhibition of lipolysis, while it
also corrects other features of atherogenic
diabetic dyslipidemia such as increasing high
density lipoprotein-cholesterol and lowering
triglycerides [25]. Better control of PPG with a
short-acting insulin secretagogue or insulin
analog was associated with increased
myocardial blood flow in patients with
T2DM [28]. A short-acting sulfonylurea has
also been shown to reduce carotid intima
thickness (CIT) in patients with T2DM, which
was associated with changes in PPG in
contrast to a longer-acting sulfonylurea,
which had an impact primarily on the FPG
levels [29]. Early intensive insulin therapy in
people who were newly diagnosed with T2DM
has been shown to reduce the inflammatory
marker tumor necrosis factor alpha and
improve endothelial function [30–33]. These
findings suggest that insulin has pleiotropic
effects on putative CV risk factors and
endothelial dysfunction.
Exposure to hyperglycemia at the onset of
diabetes initiates a vicious legacy of ‘metabolic
memory’ [34]. The overproduction of reactive
oxygen species (ROS) by the mitochondrial
electron transport chain is the underlying
mechanism of glucose- and lipid-mediated
vascular damage in diabetes facilitated by
excess production of sorbitol, advanced
glycation end-products (AGE), increased
hexosamine flux and protein kinase C (Fig. 1)
[34–36]. AGE modification of mitochondrial
DNA respiratory proteins results in excess ROS
production and cellular damage. These, along
with the increased production of peroxynitrite,
create endothelial damage that results in excess
CVD. Similarly, b cells exposed to a higher level
of ROS result in b-cell dysfunction and
increased b-cell apoptosis [13, 37, 38]. These
mechanistic studies suggest that insulin
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treatment introduced early following diagnosis
to lower blood glucose to normoglycemia will
effectively abolish gluco-lipo-toxicity and
thereby restore residual b-cell function and
reduce apoptosis [39]. Among the available
anti-diabetic drugs, only insulin allows rapid
and consistent near to normal glucose control
within a few days—even with glycated
hemoglobin (HbA1c) levels [9% at diagnosis
[40–42].
BENEFITS OF EARLY INSULIN
REPLACEMENT ON B-CELL
FUNCTION
The beneficial effect of early glycemic control
on b-cell function has been demonstrated in
several studies (Table S1) [41–51]. One of the
largest studies was conducted in China and
involved 382 persons with newly diagnosed
type 2 diabetes randomized to insulin therapy,
via either continuous subcutaneous insulin
infusion or multiple daily injections, or oral
hypoglycemic agents [41]. When
normoglycemia was achieved, treatment was
stopped and the remission rates at 1 year were
51.1%, 44.9% and 26.7%, respectively. Chen
et al. treated people with newly diagnosed
T2DM who had been hospitalized with severe
hyperglycemia with short-term intensive
insulin therapy followed by 6 months of
insulin therapy or oral anti-diabetic drugs [43].
The improved b-cell function was better
maintained with insulin therapy than with
oral drugs. In 2009, Xu et al. published
long-term follow-up results on the remission
of hyperglycemia and improved b-cell function
following intensive insulin treatment in people
with newly diagnosed T2DM with an HbA1c of
9.9 ± 2.2% at baseline [52]. After 2 years,
approximately 50% of those who completed
the study remained near-normoglycemic with
sustained improvement in b-cell function.
Remission was seen to occur more frequently
in subjects with a shorter diabetes duration and
better glucose control during intensive insulin
treatment [29, 52]. In a retrospective analysis of
a large cohort of newly diagnosed persons with
T2DM, Chon et al. demonstrated that early
insulin treatment leads to a long-lasting
improvement in b-cell function that facilitates
long-term glycemic control, compared with the
use of oral anti-diabetic drugs as first-line
therapy. The positive results observed over the
Fig. 1 The vicious circle of ‘metabolic memory’ [36]. AGEs
advanced glycation end-products, NO nitric oxide, NTF
neurotrophic factor, RAGE receptor for advanced glycation
end-product. Reproduced with permission from Drzewoski
J, Kasznicki J, Trojanowski Z. The role of ‘‘metabolic
memory’’ in the natural history of diabetes mellitus. Pol
Arch Med Wewn. 2009;119:493–500
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4-year study duration occurred irrespective of
the method of insulin delivery [53]. Harrison
et al. showed that the improvement in b-cell
function obtained with 3 months of intensive
insulin therapy plus metformin in newly
diagnosed patients with T2DM could be
preserved for at least 3.5 years with insulin
plus metformin or triple oral therapy [45]. In a
comparative study with drug-naı¨ve patients
with T2DM, basal insulin glargine
administered as first-line treatment induced a
significantly better recovery of b-cell function
(proinsulin/C-peptide ratio and homeostasis
model assessment B) than metformin, despite
both being equally effective at controlling
HbA1c in the target range [50]. Zeng et al. also
reported an improvement in b-cell function
with basal insulin glargine in newly diagnosed
patients with T2DM [54].
Few studies have compared different insulin
preparations with respect to b-cell protection.
Insulin glargine is as effective as neutral
protamine Hagedorn (NPH) insulin at
controlling HbA1c levels, but is associated with
a lower risk of hypoglycemia [55] owing to its
flatter and longer-lasting pharmacodynamic
profile and therefore has the advantage of
causing less glycemic variability. Adding
insulin glargine versus NPH to metformin
resulted in a more efficient reduction in b-cell
stress in the glargine group. Although FPG and
PPG levels did not differ between the two
treatments, glargine reduced intact pro-insulin
significantly more after lunch and dinner than
did NPH [56].
These studies all suggest that early intensive
insulin therapy allows the pancreas to rest by
reducing b-cell stress, which leads to an
improvement in b-cell function. A short course
of intensive insulin therapy also results in
significant improvements in quality of life and
treatment satisfaction [57].
EARLY INTRODUCTION OF BASAL
INSULIN ADDED TO ORAL
ANTI-DIABETIC TREATMENT
Recommendations from the new
patient-centered joint position statement of
leading experts from the American Diabetes
Association (ADA) and the European
Association for the Study of Diabetes (EASD)
suggest six options as second-line therapy if
maximally tolerated doses of metformin fail to
sufficiently control HbA1c: i.e., a sulfonylurea,
pioglitazone, sodium glucose co-transporter 2
inhibitors, dipeptidyl peptidase-4 inhibitors,
glucagon-like peptide-1 (GLP-1) analogs, and
basal insulin [12]. However, in practice, insulin
tends to be used only if dual or triple therapy at
maximal doses of combined oral anti-diabetic
drugs or GLP-1 analogs fail to achieve an HbA1c
of\7–7.5%, resulting in an unfortunate delay in
achieving good glycemic control.
The efficacy and safety of early basal insulin
in type 2 diabetes (EARLY) trial was a
non-interventional observational study
evaluating the efficacy and safety of insulin
glargine under real-world conditions in 1438
people with T2DM insufficiently controlled
with maximally tolerated doses of metformin
[58]. Insulin glargine was titrated to a target FPG
of B5.6 mmol/L resulting in a significant
decrease in HbA1c from 8.7% at baseline to
7.4% after 6 months [58, 59]. The decrease in
HbA1c was significantly greater for people with
diabetes duration of\5 years and for those with
a lower HbA1c and body mass index at baseline.
Only 2.5% of patients reported hypoglycemic
events and seven patients had severe
hypoglycemia thus the early use of insulin
glargine in these patients was seen to be
effective and well tolerated.
These findings are in accord with the analysis
of clinical trials by Fonseca et al. where more
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subjects were found to have achieved HbA1c
B7% on metformin and insulin glargine (early
insulin initiation), with the least weight gain
and risk of hypoglycemia despite a higher
insulin dose than those who were on
comparator therapies (later insulin initiation).
This supports the inclusion of basal insulin as a
rational second step in the treatment algorithm
for T2DM [60]. Pennartz et al. achieved a
sustained reduction of FPG to a target of
5.6 mmol/L with insulin glargine in subjects
failing on metformin therapy, which resulted in
an improvement in both the first- and
second-phase insulin secretion, supporting the
concept of pancreatic rest as a result of near
normal fasting plasma glucose [61].
However, an individualized patient-centered
decision is required, owing to the ever
increasing options now available as add-on
therapy to metformin.
LONG-TERM IMPACT
OF INTENSIVE GLUCOSE CONTROL
ON CV OUTCOMES
Recently, observational trials have highlighted
that CVD remains the major cause of morbidity
and mortality in people with abnormal glucose
tolerance and T2DM [62, 63]. A meta-analysis of
mega-trials with CV outcomes as the primary
objective showed that intensive glucose control
in those with long-term diabetes resulted in a
small but significant reduction in non-fatal
myocardial infarction (MI, odds ratio 0.83),
but it did not reduce the risk of all-cause
mortality or death due to CV or
cerebrovascular disease [64–66]. The first
controlled trial to report a significant benefit
of intensified glucose control on macrovascular
complications and all-cause mortality was the
Diabetes Intervention Study (DIS), the only
outcome study that specifically controlled for
(1-h) PPG in newly diagnosed people with
T2DM [67].
The UKPDS legacy evaluation, a 10-year
post-trial follow-up study of people with
T2DM receiving intensive glucose control with
insulin compared with conventional therapy,
resulted in the emergence of a significant
reduction in CV outcomes and all-cause
mortality [6]. This effect was observed despite
between-group differences in HbA1c being lost
after the first year post-trial. The authors
concluded that early intensive glucose control,
initiated as soon as diabetes has been
diagnosed, is an effective tool to prevent CV
complications over the long term [6]. The
Epidemiology of Diabetes Interventions and
Complications (EDIC) study [68], the
long-term follow-up study of the Diabetes
Control and Complications Trial (DCCT),
demonstrated a similar emergence of CV
benefits over a mean 17-year follow-up period
in people with type 1 diabetes [69]. CV benefits
were also seen with intensive and goal-oriented
polypharmacy treatment of known modifiable
risk factors in high-risk people with T2DM [44,
70]. Thus, early intervention to keep blood
glucose and HbA1c in the near to normal range
seems to be the key to reducing CV morbidity
and mortality. Although intensive glucose
control results in significant effects on
retinopathy and nephropathy within a shorter
period of time (5–10 years), significant
improvements in the primary prevention of
CVD have only been reported after a longer
period of follow-up [44, 59, 67, 69, 70].
ORIGIN
A landmark study in people with T2DM and a
high CV risk profile, ORIGIN was a
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multinational, multicenter, randomized,
controlled trial of 12,537 people with
dysglycemia including pre-diabetes and type 2
diabetes, which was designed to evaluate the
effects of insulin glargine or omega-3 fatty acids
(polyunsaturated fatty acids) on CV outcomes
in a high-risk population. CV risk was defined as
prior major CV events/disease or multiple CV
risk factors [71]. Table 1 highlights the
differences between ORIGIN and the
mega-trials Action to Control Cardiovascular
Risk in Diabetes (ACCORD) [5], Action in
Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled
Evaluation (ADVANCE) [7], and the Veterans
Affairs Diabetes Trial (VADT) [4]. Among the
differences were more macrovascular
complications, shorter diabetes duration, and
lower HbA1c levels at randomization in the
ORIGIN trial population. Also, 82% of the
ORIGIN participants had early T2DM (on 0 or
1 oral anti-diabetic drug), 6% had newly
detected T2DM, and the remaining 12% had
pre-diabetes (IFG and/or IGT), highlighting that
insulin glargine intervention was being
introduced early in the course of the disease.
In addition, glargine was titrated to reach an
FPG level of B5.3 mmol/L [71]. In the standard
care group, 5% were treated with prandial
insulin, 11% were treated with a basal insulin,
and nearly twice as many patients were treated
with sulfonylurea. There were two co-primary
outcomes, which were first the composite
endpoint of non-fatal MI, non-fatal stroke, or
CV death; and secondly the composite
endpoint of non-fatal MI, non-fatal stroke, CV
death, revascularization procedure, or
hospitalization for heart failure. ORIGIN was a
treat-to-target trial; however, a very
conservative titration algorithm was developed
because insulin glargine was initiated at such an
early stage of glucose intolerance. After a
Table 1 Baseline characteristics in ORIGIN and other cardiovascular outcome studies
ACCORD VADT ADVANCE ORIGIN
N 10,251 1791 11,140 12,537
Age (years) 62 60 66 64
Diabetes (years) 10a 11.5b 8b 5b
IFG/IGT (%) 0 0 0 12
Macrovascular complications (%) 35 40 32 59
Baseline HbA1c (%) 8.1
a 9.4b 7.5b 6.4b
Treatment target HbA1c\6%
c HbA1c\6%
c HbA1c B 6.5%
c FPG B 5.3 mmol/Ld
Intervention Multiple drugs Multiple drugs Glicazide ± others Glargine ± others
ACCORD Action to Control Cardiovascular Risk in Diabetes, ADVANCE Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modiﬁed Release Controlled Evaluation, FPG fasting plasma glucose, IFG impaired fasting glucose,
IGT impaired glucose tolerance, HbA1c glycated hemoglobin, ORIGIN Outcome Reduction With an Initial Glargine
Intervention, VADT Veterans Affairs Diabetes Trial
a Median
b Mean
c Intensive group
d B95 mg/dL (1 mmol/L = 18 mg/dL)
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median follow-up of 6.2 years and a final dosage
of 0.4 units/kg of insulin glargine
(approximately 28 units once per day), CV
outcomes were similar in both treatment arms:
2.94 vs. 2.85 events per 100 person-years in the
insulin glargine and standard care groups,
respectively [17]. Administration of insulin
glargine to patients with a history of prior CV
events was not associated with a higher
incidence of the primary outcome [hazard
ratio (HR) 0.97 (95% confidence interval (CI)
0.87–1.07)]. These data indicated that basal
insulin treatment in the form of insulin
glargine was safe in persons with type 2
diabetes with pre-existing CV events. This
finding was in contrast with the Euro Heart
Survey on Diabetes and the Heart [72] and the
Diabetes Mellitus Insulin-Glucose Infusion in
Acute Myocardial Infarction 2 (DIGAMI 2)
study [73], which suggested that insulin
intervention was associated with a higher risk
of a CV event after acute coronary syndrome.
Overall, ORIGIN demonstrated that insulin
glargine had a neutral effect on CV outcomes
and was associated with no increased risk for
serious CV events in people with pre-existing
CV risk. In the Glucose Reduction and
Atherosclerosis Continuing Evaluation
(GRACE) sub-study of ORIGIN, which included
1184 patients with carotid ultrasound at
baseline, the impact of insulin glargine
treatment on CIT was specifically evaluated
[74]. Over a median of 4.9 years, a
non-significant reduction in CIT was
demonstrated with glargine compared with
standard care. The decrease in CIT, however,
was consistent with that observed in DCCT/
EDIC, in which the benefits of improved
glucose control were observed after long-term
follow-up [73].
A secondary analysis of ORIGIN evaluated
the attainment and maintenance of HbA1c
below target of 7% [75]. Both strategies
maintained the mean HbA1c levels of 6.0 to
\6.6% for 5 years, i.e., 6.3% (range 5.8–6.9%)
with insulin glargine versus 6.6% (range
6.1–7.3%) with standard care. A total of 77%
of patients in the glargine arm versus 66% of
those in the standard care arm attained an
HbA1c of\7% after 5 years. Those participants
in the insulin glargine arm needed fewer dual
and triple combinations and complex insulin
regimens compared with those receiving
standard care (14% vs. 42%, respectively).
Rates of adverse events (e.g., severe
hypoglycemia) with insulin glargine were low
compared with those in previous outcome trials
in people with advanced diabetes; however, the
patient populations in these trials were not the
same.
Analysis of the frequency and complications
of severe hypoglycemia in ORIGIN has shown
that although the incidence of severe
hypoglycemia was higher with insulin, CV
complications and mortality were two to three
times higher when associated with severe
hypoglycemia and standard care [75, 76]. In
addition intervention with insulin glargine
reduced the incidence of diabetes among those
with pre-diabetes at randomization, despite
weight gain [17], which prevailed in the
2.7-year post-ORIGIN study [18].
Continuous subcutaneous glucose
measurements in patients receiving insulin
glargine treatment during ORIGIN showed a
stable circadian glucose profile with an HbA1c of
5.7 ± 0.4%. A low rate of nocturnal
hypoglycemic episodes after 2 years was also
observed. Glycemic variability when measured
by the mean amplitude of glycemic excursions
(MAGE) in the insulin glargine group was
2.47 ± 1.1 vs. 2.56 ± 1.28 mmol/L with
standard care [77]. ORIGIN also demonstrated
that early insulin glargine treatment resulted in
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only a moderate weight gain of 1.6 kg after
6 years [17]. In comparison, weight gain in
ACCORD and VADT was 3.5 and 4.0 kg,
respectively [4, 5]. In the Treating to Target in
Type 2 Diabetes (4-T) study, in which
participants received complex insulin
regimens, the weight increase from baseline
was 5.7 kg in the biphasic insulin aspart group
and 6.4 kg in the prandial insulin aspart group,
compared to 3.6 kg in the basal insulin (insulin
detemir) treated group [42, 78].
Insulin glargine reduced the incidence of the
composite outcome of kidney and eye disease in
patients from ORIGIN with a baseline HbA1c
C6.4% [HR 0.90 (95% CI 0.81–0.99)] compared
with standard care, but not in those participants
with a baseline HbA1c\6.4% [HR 1.07 (95% CI
0.90–1.20)] [79]. ORIGIN also demonstrated
that treatment with glargine for [6 years was
not associated with an increased risk of cancer
and cancer mortality compared with standard
care [71]. In a follow-up sub-study of ORIGIN, it
was demonstrated that achieving a target of
fasting plasma glucose \5.3 mmol/L with
insulin glargine resulted in a near normal
postprandial glucose excursion [77].
CONCLUSIONS
ORIGIN provides a relatively long-term study in
persons with pre-diabetes and type 2 diabetes
who have a high CV risk profile early in the
course of their disease. Previously, diabetes
prevention trials including Nateglinide And
Valsartan in Impaired Glucose Tolerance
Outcomes Research (NAVIGATOR) [80, 81],
involved persons with type 2 diabetes at
moderate CV risk whereas in the Diabetes
Prevention Program (DPP) [9, 82], Diabetes
Reduction Assessment with ramipril and
rosiglitazone Medication (DREAM) [83] and
the Study TO Prevent NIDDM (STOP-NIDDM)
[10] studies the participants had none or
minimal CVD. In the major CV outcomes
trials, UKPDS [3], Kumamoto [84], PROactive
[85], ACCORD [5], ADVANCE [7], VADT [4] and
STENO-2 [44], the baseline glycemic control was
in excess of 7.5%. The ORIGIN trial represents a
unique category of patients at an early stage of
their disease possessing a high CV risk profile.
The findings indicate that from a safety
perspective, the ORIGIN trial demonstrates
that basal insulin in the form of insulin
glargine does not increase CVD events in
persons with either pre-diabetes or newly
diagnosed type 2 diabetes already at high CV
risk. The extension sub-study, GRACE, provides
additional data on the evolution of CIT, which
concurs with the CV findings of the main study.
A longer period of observation will be necessary
to further clarify the truly long term safety of
insulin glargine in these subjects, as illustrated
by earlier studies in both type 1 (DCCT-EDIC)
and type 2 diabetes (UKPDS). The fact that
insulin glargine was able to reduce the fasting
plasma glucose to\5.3 mmol/L implied that the
PPG was also controlled in the majority of
subjects, which is important given the fact that
PPG level is an independent risk factor for CVD.
From the perspective of disease management
the early introduction of insulin, in an attempt
to modify the course of the disease, offers a
number of possibilities. The early use of
intensive insulin therapy in persons with type
2 diabetes with an HbA1c in the region of 9% or
more has been repeatedly demonstrated to
achieve near normal glycemia—both ambient
glycemia and glucose variability—within weeks
in most patients, and thereafter maintain this
status for up to 1 or 2 years in up to 50% of
subjects. This therapeutic approach improves
both b-cell function and insulin sensitivity,
inducing a remission, honeymoon phase of
type 2 diabetes. However, with no further
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intervention this improvement slowly
deteriorates over time. Inducing and
maintaining near-normoglycemia is a subject
of great interest with different strategies
currently being explored. Liraglutide provided
robust enhancement of b-cell function
following intensive insulin therapy in early
T2DM that was sustained over 48 weeks, but
lost when therapy was stopped [86]. Other
strategies include intermittent intensive
insulin therapy (RESET IT, ClinicalTrials.gov
NCT02192424) and the combination of
exenatide and insulin (PREVAIL,
ClinicalTrials.gov NCT02194595).
ORIGIN also included persons with
pre-diabetes in whom it was demonstrated
that disease progression was retarded on basal
insulin therapy. As this involved a relatively
small number of subjects, a longer-term
evaluation is required. This trend persisted for
approximately 3 years post-ORIGIN, as seen in
the ORIGINALE trial [18]. Identification of the
novel biomarkers involved may help to
elucidate the impact of early insulin therapy
on the progression of dysglycemia, CVD and
death [87].
Early insulin treatment therefore presents an
additional option for persons with type 2
diabetes, which is capable of restoring residual
b-cell function in the short term, providing the
basis for a better response to the different
maintenance therapies presently available.
This would be a departure from the current
guidelines, but a justifiable one both from an
efficacy and safety point of view. We therefore
propose that there are specific thresholds at
which insulin should be initiated: first,
transiently to obtain initial glycemic control;
and then later, both in early diabetes and
subsequently in later-stage disease in
combination with other anti-diabetic agents as
glycemic control worsens (Fig. 2). In ORIGIN,
insulin glargine as an early add-on treatment to
metformin was associated with a low risk of
hypoglycemia and only moderate weight gain.
No effect on CV outcomes or all-cause mortality
was shown for early insulin treatment
compared with standard care after
approximately 6 years of follow-up. However,
the recent results suggest that early insulin
attenuated the risk of microvascular outcomes
only in participants with a baseline HbA1c level
C6.4% [79]. The ADA/EASD guidelines
recommend an HbA1c B7% to reduce
microvascular complications, with a more
stringent goal of\6.5% in selected individuals.
This more stringent goal in selected individuals
is in line with the findings from ORIGIN.
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